Comparable stake leader
venBio Global Strategic Fund III, L.P.
SEC ownership of RayzeBio, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001825367.
Disclosed value leader
venBio Global Strategic Fund III, L.P.
Comparable rows
0/3
Latest evidence
19 Sep 2023
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
venBio Global Strategic Fund III, L.P.
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
19 Sep 2023
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001825367
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of RayzeBio, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
venBio Global Strategic F...
Disclosed value leader
venBio Global Strategic F...
Comparable rows
0/3
Latest evidence
19 Sep 2023
3/4/5
Highest disclosed value: $322,385,125
3 rows are not safely comparable across share classes.
Quick read
venBio Global Strategic Fund III, L.P. has the largest disclosed position value at $322.39M.
0 of 3 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens venBio Global Strategic Fund III, L.P.'s linked filing trail.
Disclosed position value
Top 3
venBio Global Strategic Fund III,...
$322.39M
Redmile Group, LLC
$116.11M
Wellington Biomedical Innovation ...
$97.37M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-3 of 3 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| venBio Global Strategic Fund III, L.P. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$322,385,125
5,158,162 shares
|
— | 19 Sep 2023 |
| Redmile Group, LLC |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$116,106,625
1,857,706 shares
|
— | 19 Sep 2023 |
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$97,365,375
1,557,846 shares
|
— | 19 Sep 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 04 Jul 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-16 of 16 reporting-owner rows connected to RayzeBio, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
16
Largest Forms 3/4/5 holder
venBio Global Strategic Fund III, L.P.
Net 12M change
$0
Latest report
26 Feb 2024
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| venBio Global Strategic Fund III, L.P. | 10%+ Owner | $322,385,125 | Mixed | 19 Sep 2023 | ||
| Redmile Group, LLC | 10%+ Owner | $116,106,625 | Mixed | 19 Sep 2023 | ||
| Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | 10%+ Owner | $97,365,375 | Mixed | 19 Sep 2023 | ||
| Richard A. Heyman | Director | $0 | Mixed | 26 Feb 2024 | ||
| Kenneth Song | PRESIDENT AND CHIEF EXECUTIVE, Director | $0 | Mixed | 26 Feb 2024 | ||
| VIKING GLOBAL INVESTORS LP | 10%+ Owner | $0 | Mixed | 26 Feb 2024 | ||
| Maha Katabi | Director | $0 | Mixed | 26 Feb 2024 | ||
| Susan Moran | Chief Medical Officer | $0 | Mixed | 26 Feb 2024 | ||
| Arvind Kush | Chief Financial Officer | $0 | Mixed | 26 Feb 2024 | ||
| Angie You | Director | Mixed | 26 Feb 2024 | |||
| Aaron Royston | Director | Mixed | 14 Sep 2023 | |||
| Versant Ventures VII GP-GP, LLC | 10%+ Owner | Mixed | 14 Sep 2023 | |||
| Mary Tagliaferri | Director | Mixed | 26 Feb 2024 | |||
| Yi Larson | Director | Mixed | 26 Feb 2024 | |||
| Christy J. Oliger | Director | Mixed | 26 Feb 2024 | |||
| Timothy van Hauwermeiren | Director | Mixed | 26 Feb 2024 |
Recent insider transactions for RayzeBio, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.